Figure 5.

S100A8 and S100A9 suppress tumorigenesis induced by xenograft of EoL-1 and EoL-1-1R in NOD-SCID mice. (A–F) Five-week-old female NOD-SCID (NOD.CB17-Prkdcscid/J) mice were divided into six groups (n = 5 per a group) as described in the materials and methods: untreated, control, S100A8 treatment (0.5 and 1 mg doses), and S100A9 treatment (0.5 and 1 mg doses). The control, S100A8 treatment, and S1009 treatment groups were subcutaneously inoculated in the shoulder with EoL-1 cells (2 × 10⁷/100 μL) (A–C) or EoL-1-IR cells (1 × 10⁷/100 μL) (D–F). Treatment groups were subsequently administered subcutaneous doses of 0.5 or 1 mg S100A8 or S100A9 at days 5 and 7 after cell inoculation. The untreated group was injected with vehicle (PBS). Tumor volume (day 1–11) and tumor weight (day 11) were measured (A,B,D,E). Tumor mass was examined for detecting phospho-PDGFRα, PDGFRα, and Ki-67, applying immunohistochemistry and hematoxylin and eosin stain (Scale bar: 200 μm) (C,F), or subjected to Western blotting to determine phosphorylation and nonphosphorylation of PDGFRα, STAT3, AKT, ERK1/2, p38 MAPK, and JNK (G). β-actin was used as the internal control. *p < 0.05 indicates a significant difference between the control and stimulator-treated groups.